168
Participants
Start Date
April 3, 2019
Primary Completion Date
February 18, 2023
Study Completion Date
April 22, 2025
Oral Cabotegravir (CAB)
30 mg tablets administered orally
Oral Rilpivirine (RPV)
25 mg tablets administered orally
Long-Acting Injectable Cabotegravir (CAB LA)
Administered by intramuscular (IM) injection
Long-Acting Injectable Rilpivirine (RPV LA)
Administered by intramuscular (IM) injection
Combination Antiretroviral Therapy (cART)
Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens were not provided through the study.
Soweto CRS, Site 8052, Soweto
Wits RHI Shandukani Research Centre CRS, Johannesburg
Umlazi CRS, Umlazi
Famcru Crs, Tygerberg Hills
Siriraj Hospital Mahidol University, Bangkok
Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore
Emory University School of Medicine NICHD CRS, Atlanta
Pediatric Perinatal HIV NICHD CRS, Site 5127, Miami
Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai
Baylor-Uganda CRS, Kampala
Baylor College of Medicine/ Texas Children's Hospital NICHD CRS, Houston
Univ. of Colorado Denver NICHD CRS, Aurora
Usc La Nichd Crs, Los Angeles
Lurie Children's Hospital of Chicago (LCH) CRS, Chicago
St. Jude Children's Research Hospital CRS, Memphis
Gaborone CRS, Gaborone
Molepolole CRS, Site 12702, Molepolole
MU-JHU Care Limited CRS, Kampala
Collaborators (1)
ViiV Healthcare
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH